Posted on Thursday, January 31st, 2013 | In Biotech
Contributed by: M. E. Garza (http://www.biomedreports.com) -
Immediately after Tekmira (NASDAQ:TKMR) (TSX:TKM) announced that it had settled litigiation between it and Alnylam Pharmaceuticals (NASDAQ:ALNY), Byron Capital analyst Douglas Loe maintained his SPECULATIVE BUY rating on the company, but raised his price target on shares a full $5, to $12.50.
About M. E. Garza (http://www.biomedreports.com)
M.E. Garza is the Co-Founder of BiomedReports.com. A two-time Emmy nominated television producer and entrepreneur, Garza's background in media, writing, marketing and public affairs has allowed him to lead and establish various companies in the broadband, entertainment and communications field. He resides in Los Angeles and his passion is tracking the latest advances in biotechnology- which gives him "great hope and promise" for the future of mankind. He is a constant student of the market who believes that the biotech sector is completely unique and dynamic sector- where everything from research to financial models and the rules for market analysis from other sectors just don't apply. He hopes to help guide BioMedReports into a leading publication that will help investors realize the potential of this revolution in finance and science, while shining the spotlight on companies that are attempting to change our lives in so many beneficial ways.